Investor Presentaiton

KEY BUSINESS SEGMENTS DOMESTIC FORMULATIONS EXPORT FORMULATIONS SUBSIDIARIES NATCO API BUSINESS Overview (1) Three key business segments: Oncology, Specialty Pharma, Cardiology and Diabetology Strong brand position in the domestic oncology Specialist sales force of nearly 550 personnel and ~1,000 distributors Strengthened C&D portfolio through additional 250+ sales force Launched 11 new products across oncology and C&D Targeting 20 product launches a year with over 12% growth Strengthening the gastroenterology, critical care, oncology and cardio-diabetes portfolios with expanded geographical, disease and therapy area coverage. Focused on niche opportunities in the US, Canada and emerging markets Integration of Dash Pharmaceuticals LLC complete and name changed to Natco Pharma USA LLC Focus on Para IV and First-to-File molecules Strengthening presence in South-east Asia, MENA and LATAM among other ROW markets by registering our niche product portfolio in these countries. • Operations in Brazil, Canada, Singapore, Australia and Philippines Amongst top 10 generic companies by sales revenue in Canada. Strong portfolio of Oncology, cardiovascular and CNS therapies In Brazil, continued to increase our presence in the Oncology and primary healthcare segments with strong market share in Everolimus and Apixaban Building a strong product portfolio in Singapore in both Tender and Private segments. • 45 active DMFs (2) in the US with niche products under development Exports focused on US, Europe and emerging markets Oncology APIs and specialty products Difficult-to-make chemistry with long synthesis. Expanding our portfolio. oligonucleotide 1.As of March 31, 2023 2.As of Sept 30, 2023 5

View entire presentation